Treatment of chronic graft-versus-host disease with Sulfasalazine in allogeneic bone marrow transplantation

Acta Haematologica

Volumn 102, Issue 2, 1999, Pages 107-109

  Okada, Masaya ^a   Okamoto, Takahiro ^a   Yamada, Shinji ^a   Yamada, Shu ^a   Itoh, Tohru ^a   Mori, Ako ^a   Saheki, Kaname ^a   Takatsuka, Hiroyuki ^a   Wada, Hiroshi ^a   Tamura, Amane ^a   Fujimori, Yoshihiro ^a   Takemoto, Yoshinobu ^a   Kakishita, Eizo ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TACROLIMUS; IMMUNOLOGICAL ADJUVANT;

ABDOMINAL PAIN; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DIARRHEA; GRAFT VERSUS HOST REACTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SHORT SURVEY; ALLOTRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; DRUG COMBINATION; MULTIMODALITY CANCER THERAPY; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PREDNISOLONE; SULFASALAZINE; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0032608388     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000040981     Document Type: Short Survey

References (10)

1. Gaginella TS, Walsh RE: Sulfasalazine: Multiplicity of action. Dig Dis Sci 1992;37:801-812.
2. Wanders A, Tufveson G, Gerdin B: The enhancing effect of cyclosporine A and sulfasalazine on the prevention of rejection in rat cardiac allografts. Transplant Int 1988;1:113-115.
3. Fay JW, Wingard JR, Antin JH, Collins RH, Pineiro LA, Blazar BR, Saral R, Bierer BE, Przepiorka D, Fitzsimmons WE, Maher RM, Weisdorf DJ: FK506 (Tacroliraus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogeneic bone marrow transplantation. Blood 1996:87:3514-3519.
4. Rains CP, Noble S, Faulds D: Sulfasalazine: A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 1995;50:137-156.
5. Bird HA: Sulphasalazinc, sulphapyridine or 5-aminosalicylic acid - Which is the active moiety in rheumatoid arthritis? Br J Rheumatol 1995;34:16-19.
6. Fujiwara M, Mitsui K, Yamamoto I: Inhibition of proliferative responses and interleukin 2 productions by salazosulfapyridine and its metabolites. Jpn J Pharmacol 1990;54:121-131.
7. Wanders A, Tufveson G, Gerdin B: Enhancement of the effect of low-dose cyclosporin A by sulphasalazine in prevention of cardiac allograft rejection in the rat. Transplant Int 1992;5: 155-158.
8. Foster GR: Behçet's colitis with oesophageal ulceration treated with sulphasalazine and cyclosporin. J R Soc Med 1988;81:545-546.
9. Laasila K, Leirisalo-Repo M: Side effects of sulphasalazine in patients with rheumatic diseases or inflammatory bowel disease. Scand J Rheumatoll 1994;23:338-340.
10. Selby W: Current management of inflammatory bowel disease. J Gastroenterol Hepatol 1993;8:70-83.